证券代码：600538 证券简称：国发股份 公告编号：临2025-025 特此公告。 北海国发川山生物股份有限公司 北海国发川山生物股份有限公司（以下简称"公司"）近日收到独立董事曾艳琳女士的书面辞职报告。曾 艳琳女士因个人原因向公司董事会提出辞去公司第十一届董事会独立董事、董事会提名委员会主任委员 和董事会战略委员会委员的职务，辞职后不再公司担任任何职务。截至本公告披露日，曾艳琳女士未直 接或间接持有公司股份，亦不存在应当履行而未履行的承诺事项。 根据《中华人民共和国公司法》《上市公司独立董事管理办法》《上海证券交易所股票上市规则》《上 海证券交易所上市公司自律监管指引第1号一一规范运作》以及《公司章程》等相关规定，由于曾艳琳 女士辞职将导致公司独立董事人数少于董事会人数的三分之一，且董事会提名委员会及战略委员会中独 立董事所占比例不符合《上市公司独立董事管理办法》以及公司章程的规定，其辞职报告将在公司股东 大会选举产生新的独立董事后生效。在此之前，曾艳琳女士将按照有关规定继续履行独立董事及其在董 事会专门委员会中的相应职责。 曾艳琳女士在担任公司独立董事期间，勤勉尽责、认真履行职责，充分行使职权，为公司规 ...

Core Insights - The pet economy in China has surpassed 500 billion yuan, maintaining over 20% growth for five consecutive years, driven by social changes, evolving consumer attitudes, and technological advancements [1][4]. Group 1: Observations on the Pet Economy - The pet product consumption is experiencing a refined upgrade, with functional cat food and high-end products growing over 50%, and smart pet products expanding at an annual rate of 35% [4][5]. - The pet service sector has developed a dual-layer consumption structure, with basic services like pet grooming seeing a 180% increase in search volume, and pet insurance adoption rates quadrupling over three years [5]. Group 2: Driving Factors Behind Pet Economy Growth - Social changes, such as aging and declining birth rates, have redefined family structures, with pets providing emotional support for lonely individuals [6]. - There is a shift in consumer perception, with younger generations viewing pets as family members, leading to increased spending on pet-related products and services [7]. - Technological innovations, including IoT and AI, are reshaping the pet industry, enhancing efficiency and standardization [8]. Group 3: Challenges and Concerns in the Industry - The pet market faces issues such as fraudulent practices in live pet trading and a lack of standards in pet food, leading to a 120% increase in consumer complaints in 2024 [10]. - Intense competition has emerged due to significant capital influx, resulting in a "price war" among brands, particularly in the pet supplies sector [11]. - Regulatory frameworks are lagging, with a lack of unified standards in emerging areas like pet insurance and veterinary services [12]. Group 4: Future Trends in the Pet Economy - The industry is expected to see a parallel growth in smart and health-focused products, with health-related spending projected to exceed 40% of total pet expenditures [13]. - Professionalization and standardization of services are anticipated, with leading companies enhancing service quality through brand and chain development [14]. - Cross-industry integration is likely to create new business models, such as pet-themed hotels and training courses, expanding the consumption landscape [15]. Group 5: Benefiting Companies - Guobao Pet is projected to generate 5.244 billion yuan in revenue in 2024, leading the domestic pet business sector, with a 34.82% year-on-year increase in Q1 2025 revenue [16]. - Zhongchong Co. is expected to achieve 4.464 billion yuan in revenue in 2024, ranking second, with a 25.41% year-on-year increase in Q1 2025 revenue [16]. - Tianyuan Pet is anticipated to reach 2.764 billion yuan in revenue in 2024, ranking third among domestic pet companies [16]. - Yuanfei Pet, a leading global pet leash manufacturer, has over 90% of its products exported, with a significant portion of high-margin products [17]. - Ruipu Bio is collaborating with veterinary hospitals to enhance its pet medical services, projecting 690 million yuan in revenue for 2024 [17]. - Yiyi Co. is focusing on disposable pet hygiene products, with a projected revenue of 1.798 billion yuan in 2024 [19].

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

证券代码：688526 证券简称：科前生物 公告编号：2025-026 武汉科前生物股份有限公司 第四届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 武汉科前生物股份有限公司（下称"公司"）于 2025 年 5 月 19 日以现场和通讯相结合的形式召开第四届监事会第九次会议（下称 "本次会议"）。本次会议通知于 2025 年 5 月 14 日以邮件、电话的 方式向各位监事发出，本次会议由监事会主席吴斌先生主持，本次会 议应参与表决监事 3 人，实际参与表决监事 3 人。本次会议的召集、 召开程序均符合《公司法》、《证券法》等法律、法规和规范性文件 以及《公司章程》的规定。 二、监事会会议审议情况 经与会监事审议，作出决议如下： (一）审议通过《关于公司与华中农大签订合作研发协议暨关联 交易的议案》 监事会认为：公司本次签订合作研发协议暨关联交易符合公司整 体发展方向，本次关联交易的审批程序合法合规，不存在损害公司及 股东利益的情形。 具体内容详见公司于同日刊登在上海证券 ...

证券代码：600201 证券简称：生物股份 公告编号：临 2025-027 金宇生物技术股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 05 月 27 日(星期二) 下午 15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 05 月 20 日(星期二) 至 05 月 26 日(星期一)16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 stock@jinyu.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 金宇生物技术股份有限公司（以下简称"公司"）已于 2024 年 4 月 25 日披 露公司《2 ...

Investment Rating - The report adjusts the investment rating to "Recommended" with a target price of 7.8 CNY [2][8] Core Views - The company is facing operational pressure with a significant decline in revenue and net profit for 2024, but there are signs of improvement in Q1 2025 [2][8] - The company has been focusing on R&D and innovation to diversify its product offerings, which is expected to enhance its resilience and future growth potential [8] Financial Performance Summary - For 2024, the company reported total revenue of 1.255 billion CNY, a year-on-year decrease of 21.45%, and a net profit of 109 million CNY, down 61.58% [2][4] - In Q1 2025, the company achieved revenue of 352 million CNY, a slight increase of 1.06% year-on-year, while net profit was 76.48 million CNY, down 27.57% [2][4] - The gross margin for 2024 was 53.86%, a decline of 5.33 percentage points, marking the lowest level since 2011 [8] Revenue and Profit Forecast - Projected revenues for 2025, 2026, and 2027 are 1.514 billion CNY, 1.750 billion CNY, and 2.018 billion CNY, respectively, with expected growth rates of 20.6%, 15.6%, and 15.3% [4][8] - Forecasted net profits for the same years are 197 million CNY, 250 million CNY, and 316 million CNY, with growth rates of 80.7%, 27.2%, and 26.2% [4][8] Product Development and Market Strategy - The company is actively investing in R&D to develop new products across various categories, including non-oral vaccines and pet vaccines, which is expected to diversify its product matrix and improve its market position [8] - The company aims to reduce reliance on a single product line, particularly the foot-and-mouth disease vaccine, which has seen significant sales declines [8]

Group 1 - The China Livestock Breeding Index (930707) has shown a slight increase of 0.18% as of May 19, 2025, with notable gains in stocks such as Xiangjia Co., Ltd. (002982) up by 6.62% and Yike Foods (301116) up by 1.73% [1] - The recent outbreak of highly pathogenic avian influenza in Brazil has led to a suspension of poultry imports from Brazil by Mexico, impacting the poultry market [1] - A report from Guojin Securities indicates that the price of white feather chickens has rebounded due to previous price drops and improved consumer demand, while the supply of breeding chickens has significantly decreased year-on-year [1] Group 2 - The macroeconomic policy adjustments are expected to gradually boost consumer demand, leading to an increase in poultry product consumption and a higher proportion of high-end products [2] - The dairy industry is anticipated to stabilize and recover in the second half of 2025, with ongoing low prices for raw milk and an acceleration in industry capacity reduction [2] - The top ten weighted stocks in the China Livestock Breeding Index account for 69.38% of the index, with companies like Haida Group (002311) and Muyuan Foods (002714) being the most significant contributors [3]

北京海润天睿律师事务所 关于青岛蔚蓝生物股份有限公司 法律意见书 中国·北京 地址：朝阳区建外大街甲 14 号广播大厦 5 层、9 层、10 层、13 层、17 层 邮编：100022 电话： （010）65219696 传真： （010）88381869 二〇二五年五月 北京海润天睿律师事务所 关于青岛蔚蓝生物股份有限公司 致：青岛蔚蓝生物股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受青岛蔚蓝生物股份有限 公司（以下简称"公司"）的委托，指派本所律师出席公司 2024 年年度股东会， 并依据《中华人民共和国公司法》 （以下简称" 《公司法》"）、 《上市公司治理准则》 《公司章程》及其他相关法律、法规的规定，就公司本次股东会的召集、召开程 序、出席会议人员的资格、召集人资格、表决程序及表决结果等有关事宜出具本 法律意见书。 对本法律意见，本所律师声明如下： 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-022 青岛蔚蓝生物股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 本次会议是否有否决议案：无 审议结果：通过 一、 会议召开和出席情况 (一) 股东会召开的时间：2025 年 5 月 16 日 (二) 股东会召开的地点：青岛市崂山区九水东路 596-1 号 蔚蓝生物创新园 B 座 多媒体会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 份总数的比例（%） (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东会由公司董事会召集，采用现场投票和网络投票相结合的方式召开。 现场会议由公司董事长陈刚先生主持。会议召集、召开和表决程序符合《公司法》 及《公司章程》的规定。 (五) 公司董事、监事和董事会秘书的出席情况 股东会。 二、 议案审议情况 (一) 非累积投票议案 表决情况： | | 同意 | | | 反对 | | 弃权 | | | | --- | --- | --- | ...

股 票 代 码 ： 000518 股票简称：四环生物 公 告 编 号 ： 临 -2025-30 号 江苏四环生物股份有限公司 第十届董事会第十二次会议决议公告 江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 5 月 12 日在公 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 司会议室以现场结合通讯的方式召开了第十届董事会第十二次会议。本公司于 记载、误导性陈述或重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日在公 司会议室以现场结合通讯的方式召开了第十届董事会第十二次会议。公司于 2025 年 5 月 5 日以通讯方式发布了召开董事会的通知。出席会议董事应到 5 名，实到 司章程》有关规定，形成的决议合法、有效。 一、审议通过了关于改选公司第十届董事会部分董事的议案； 鉴于公司实际控制人已发生变更，公司第十届董事会拟进行改选，经公司控 股股东福建碧水农业投资有限公司提名，董事会提名委员会审查通过，公司董事 会同意提名邱为碧先生、陈龙先生、韦麟福先生为第十届董事会非独立董事候选 人，任期自公司2025年第二次临时股东大会审议通过之日起 ...